Westlake Pharmaceuticals (Hangzhou) Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private, Subsidiary
- Established
- 2020-09-23
- Employees
- -
- Market Cap
- -
- Website
- https://www.wp-hz.com/
Study of WPV01 in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy Participants
- Interventions
- Drug: WPV01 Dose 1-4Drug: WPV01 Dose 5-8 and RitonavirDrug: WPV01 Dose 9-12Drug: WPV01 Dose 13-15 and RitonavirDrug: WPV01 Dose 16
- First Posted Date
- 2024-01-16
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Westlake Pharmaceuticals (Hangzhou) Co., Ltd.
- Target Recruit Count
- 108
- Registration Number
- NCT06205329
- Locations
- 🇨🇳
Shulan(Hangzhou) Hospital, Hangzhou, China
Phase III Clinical Study Evaluating the Efficacy and Safety of WPV01 in Patients With Mild/Moderate COVID-19
- First Posted Date
- 2024-01-09
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Westlake Pharmaceuticals (Hangzhou) Co., Ltd.
- Target Recruit Count
- 1350
- Registration Number
- NCT06197217
- Locations
- 🇨🇳
China Japan Friendship Hospital, Beijing, Beijing, China
Study of WPV01 Compared With Placebo in Patients With Mild/Moderate COVID-19 Infection
- First Posted Date
- 2023-03-02
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Westlake Pharmaceuticals (Hangzhou) Co., Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT05752175
- Locations
- 🇨🇳
Shulan(Hangzhou) Hospital, Hangzhou, China